PDSB - PDS Biotechnology inks partnership with Head and Neck Cancer Alliance

PDS Biotechnology (PDSB) and the Head and Neck Cancer Alliance announce a new partnership to raise awareness of new and developing treatment options for patients with HPV-attributed head and neck cancer diagnoses.PDS's lead candidate, PDS0101, uses versamune to activate the immune system to recognize HPV-associated cancer cells and respond by inducing T-cells to attack and destroy them.The company had posted results from Phase II triple combination study of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies, last week.Shares down 1% premarket.

For further details see:

PDS Biotechnology inks partnership with Head and Neck Cancer Alliance